Tag: Solid Tumors
FDA Grants Fast Track Designation to DB-1303 for the Treatment of...
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to DB-1303 a novel antibody-drug conjugates for the treatment of patients with advanced, recurrent or metastatic endometrial carcinoma with HER2 over-expression who have progressed on or after standard systemic treatment.
Initial Dose-Escalation of First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in...
An ongoing, phase 1 dose-escalation study investigating XB002, Exelixis’ next-generation tissue factor-targeting antibody-drug conjugate (ADC) for the treatment of patients with advanced solid tumors, has shown promising results.
First Patient Dosed in Phase 1 Clinical Trial of ADC Therapeutics’...
A first patient has been dosed in a Phase 1 clinical trial evaluating ADCT-901, targeting kidney-associated antigen 1 (KAAG1), in patients with selected advanced...
FDA Approves Sacituzumab Govitecan for Adult Patients with Unresectable Locally Advanced...
This week the U.S. Food and Drug Administration (FDA) has granted full approval to Sacituzumab Govitecan* (Trodelvy®; Gilead Sciences) for the treatment of adult...
ASCO 2020 – Advancing Antibody-drug Conjugates: Sacituzumab Govitecan
With a growing number of antibody-drug conjugates being approved by regulatory agencies around the world and promising clinical benefits seen in investigational agents, the...
Updated Analysis from Ongoing Phase I Trial of DS-8201 Confirms Significant...
About one in five breast cancers overexpress HER2, a tyrosine kinase receptor growth-promoting protein found on the surface of some cancer cells, which is...
Tisotumab vedotin Demonstrates Encouraging Response Rate and a Manageable Safety Profile...
Preliminary clinical data for tisotumab vedotin, also known as HuMax®-TF-ADC from a Genmab-sponsored phase I/II clinical trial (GEN 701) were featured today in an...
Phase I Clinical Trial of Radioimmunotherapeutic FF-21101 Initiated in Patients with...
Earlier this week Strategia Therapeutics, an integrated pharmaceutical company, announced that it had initiated a Phase I clinical trial of Fujifilm's radioimmunotherapeutic agent FF-21101 (90Y) in...
Compugen’s Antibody Drug Conjugate Program Results Presented
This week, during the World ADC Summit being held October 19 - 22, 2015 in San Diego, CA, Compugen presented the status of its predictive...
Antigen Shedding and Targeted Delivery of Immunotoxins in Solid Tumors: A...
Cells modulate responses to signals in the extracellular environment by shedding cell surface antigens. Understanding this process is important because antibody-based anti-cancer therapies target...
